Setup

COMPASS Pathways (CMPS) filed its FY2025 10-K confirming both pivotal Phase 3 trials for COMP360 psilocybin therapy in treatment-resistant depression hit primary endpoints at p<0.001. The company has ≈$493M in pro forma cash and an explicit NDA submission target of Q4 2026. The clinical program is de-risked. The remaining question is whether the DEA will reschedule psilocybin from Schedule I — a mandatory prerequisite for commercialization that sits outside FDA's jurisdiction and outside management's control.

What the filing says

Both trials delivered clean wins. COMP005 (n=258, monotherapy): -3.6 MADRS points vs placebo at week 6, p<0.001. Part B showed 25% durable response through 26 weeks on 1-2 doses. COMP006 (n=581, repeat dosing): -3.8 MADRS points vs 1mg active control, p<0.001, with 39% achieving clinically meaningful response.

Management committed to NDA submission Q4 2026 after reporting COMP006 26-week durability data in "early third quarter." FDA accepted a meeting request for rolling submission discussions. Breakthrough Therapy Designation has been held since 2018.

New risk language in this filing: the scheduling process "may be subject to potential impacts of regulatory agency staffing cuts and policy changes." MNMD's 10-K uses identical language, explicitly naming DOGE. Cross-ticker validation from ACHV and CERT filings confirms this is systemic — KalVista became the first confirmed PDUFA miss from DOGE staffing cuts.

Capital structure: $493M pro forma cash (82% of market cap), clean PwC audit, no going concern, runway into 2028. Share count roughly doubled in two years to ≈130M, with 42M more in warrants outstanding.

What the market thinks

At $5.34, the implied option value for COMP360 — a dual Phase 3-winning, BTD-holding, NDA-stage asset — is ≈$107M. Benchmarked against Spravato's $2B+/yr run rate (57% YoY growth, JNJ guiding $3-3.5B by 2027-28) and a $2.5-3.5B commercial NPV range, the market prices roughly 4-9% probability that COMP360 ever reaches patients.

The options market tells a split story. Near-term: May puts outnumber calls 2.2:1, anchored by a 25,169-contract wall at the $7 put — institutional hedges from the February $8.00 offering. Long-term: Jan 2027 LEAPS are 48:1 calls to puts, Jan 2028 is 18:1 with 3,319 contracts at $12. Near-term money is hedging. Long-term money is positioning for the NDA window.

Factor regression (250 days, CMPS ~ SPY + XBI) shows the 33.7% one-month selloff is 106% idiosyncratic — XBI dropped just 2.5% over the same period. The clinical data hasn't changed. This is a price move, not a thesis move. The most likely drivers: post-offering float expansion (55% in one month), institutional stop-loss cascades from $8 buyers now at $5.34, and psychedelic sector contagion from the MDMA/Lykos rejection.

Why the gap exists

1. The DEA gate is structural and unprecedented. Psilocybin is Schedule I. FDA approval alone doesn't trigger rescheduling — that requires a separate HHS scientific evaluation followed by DEA notice-and-comment rulemaking. DEA forwarded a rescheduling petition to HHS in August 2025 (per a Ninth Circuit ruling in Aggarwal v. DEA), but HHS hasn't responded. No timeline exists. The MDMA/Lykos rejection (9-2 advisory committee vote against, August 2024) left scar tissue across the sector. The market is collapsing this uncertainty to "probably won't happen," which is defensible given the precedent vacuum — even though DEA's own actions (petition forwarded, production quotas up 67%, cannabis rescheduling EO) point toward engagement rather than obstruction.

2. Post-offering supply mechanics. The February 2026 raise added ≈53M shares to a 96M float. Institutional buyers at $8 approaching stop-loss territory creates a selling-begets-selling dynamic that's mechanical and temporary but dominates the tape.

3. A cross-ticker signal that hasn't been synthesized. Neuronetics (STIM) disclosed on their March 17 earnings call that they're actively building COMP360 launch infrastructure — identified initial centers, working with COMPASS on payer coverage, CMO participated in a January 2026 launch planning webinar. STIM operates 84 Spravato clinics nationally and says COMP360 requires "limited incremental investment" given existing REMS infrastructure. A commercial delivery partner spending real operational resources on launch prep is a meaningful signal about expected scheduling outcomes. This requires reading STIM's transcript and connecting it to CMPS — a synthesis that doesn't exist in any single analyst report.

For additional context on clinical comparables: COMP360's effect sizes (-3.6, -3.8 MADRS) are in line with esketamine's TRANSFORM-2 (-4.0, p=0.010). But Spravato's TRANSFORM-1 trial failed. CMPS has two positive Phase 3s — a stronger NDA package than what got esketamine approved. And COMP360 shows durability on 1-2 doses versus Spravato's ongoing maintenance requirements.

Risks (ranked by impact)

1. DEA scheduling extends 3+ years. HHS evaluation hasn't started. Cannabis rescheduling under the same administration remains "pending" months after an executive order. If psilocybin follows a similar path, launch pushes to 2029+ and the cash cushion gets tested. Entirely outside management's control.

2. FDA review delayed by DOGE staffing cuts. CDER lost 473 net employees in FY2025. PDUFA on-time rate dropped to ≈78%. CMPS's NDA enters review in 2027, right when cuts are fully biting. BTD provides priority review but doesn't eliminate the bottleneck.

3. Dilution erodes per-share value. Fully diluted count could reach 170M+ (from 96M at year-end 2025). PIPE warrants at $9.93 and ≈29M pre-funded warrants create selling pressure on rallies. Unused $150M ATM facility adds overhang.

4. Reimbursement fails for the delivery model. COMP360 requires 6-8 hour therapist-supervised sessions — a substantially different operational footprint than Spravato's 2-hour monitoring. Payer willingness to reimburse is unproven.

5. MDMA precedent repeats. Lykos/MAPS had Phase 3 data and got rejected on trial design concerns. CMPS used a 1mg active control to address functional unblinding, but an advisory committee could still raise similar objections.

Catalysts (with dates)

• March 26, 2026: Earnings call. Management read on FDA pre-NDA meeting outcome and rolling submission status.
• Q3 2026 (early): COMP006 26-week durability data. Completes the NDA package.
• Q4 2026: NDA submission. The major re-rating event — transitions from "will they file?" to "will FDA approve?"
• Q1 2027: FDA filing acceptance / PDUFA date assignment.
• TBD: HHS scheduling recommendation. The black box that resolves the biggest risk.

What would change our mind

Bearish: DEA issues a statement indicating resistance to psilocybin rescheduling, or HHS returns a negative scientific evaluation. This shifts the scheduling factor from "timeline risk" to "binary block." Separately: NDA submission delayed beyond Q4 2026 tightens the cash narrative and stalls the catalyst sequence.

Bullish: HHS responds favorably to the DEA petition. This compresses the scheduling timeline from years to months and removes the primary discount. Insider buying at $5-6 would provide a management confidence signal that's currently absent — founders sold $17M in October 2024, ATAI sold $16M in September 2024, no buying since.

Evidence